Ligand PharmaceuticalsLGND
LGND
About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Employees: 68
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
16% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 85
16% more call options, than puts
Call options by funds: $999K | Put options by funds: $860K
14% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 29
1% more funds holding
Funds holding: 255 [Q4 2024] → 257 (+2) [Q1 2025]
1% more capital invested
Capital invested by funds: $1.95B [Q4 2024] → $1.96B (+$11.1M) [Q1 2025]
0.42% more ownership
Funds ownership: 96.46% [Q4 2024] → 96.89% (+0.42%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$145
19%
upside
Avg. target
$145
19%
upside
High target
$145
19%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Trevor Allred | 19%upside $145 | Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Based on 4 articles about LGND published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum.
Neutral
GlobeNewsWire
1 week ago
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025 JUPITER, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced the completion of its previously announced merger between the company's wholly owned subsidiary, LNHC, Inc., and CHRO Merger Sub Inc., a wholly owned subsidiary of Channel Therapeutics Corporation (“Channel”).
Neutral
GlobeNewsWire
1 week ago
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name “Pelthos Therapeutics Inc.” and will trade on the NYSE American exchange under the ticker symbol “PTHS” starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Merger Sub Inc. (“Merger Sub”), a wholly owned subsidiary of Channel Therapeutics Corporation (“Channel”), merged with and into LNHC, Inc. (“LNHC”), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND), with LNHC surviving as a wholly owned subsidiary of Channel (the “Merger”).
Positive
Seeking Alpha
2 weeks ago
Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. LGND's business model supports sustainable revenue through royalties and partnerships with leading pharma firms.
Neutral
GlobeNewsWire
1 month ago
Ligand Announces 2025 Investor Day in New York City
JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m.
Neutral
GlobeNewsWire
1 month ago
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025.
Neutral
Seeking Alpha
2 months ago
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chief Executive Officer Rich Baxter – Senior Vice President-Investment Operations Tavo Espinoza – Chief Financial Officer Lauren Hay – Vice President-Strategic Planning and Investment Analytics Conference Call Participants Doug Miehm – RBC Capital Markets Matt Hewitt – Craig-Hallum Trevor Allred – Oppenheimer Annabel Samimy – Stifel John Vandermosten – Zacks Operator Thank you for standing by. My name is Kate and I will be your conference operator today.
Neutral
GlobeNewsWire
2 months ago
Ligand Reports First Quarter 2025 Financial Results
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.
Neutral
GlobeNewsWire
2 months ago
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.
Neutral
GlobeNewsWire
2 months ago
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025.
Charts implemented using Lightweight Charts™